雙成藥業(002693.SZ)一季度預虧200萬元-400萬元
格隆匯4月14日丨雙成藥業(002693.SZ)披露2021年第一季度業績預吿,公司預計2021年1-3月實現歸屬於上市公司股東的淨利潤為虧損200萬元-400萬元,上年同期為虧損526.02萬元。
報吿期內,公司依託現有的生產經營,主營業務收入有所增長,報吿期內整體業績較上年同期好轉,虧損減少。
預計報吿期內非經常性損益對淨利潤的貢獻金額約為312萬元左右,主要系按期攤銷進入損益的政府補助收入及理財收益等所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.